AR093726A1 - A COMPOSITION THAT INCLUDES METFORMIN - Google Patents
A COMPOSITION THAT INCLUDES METFORMINInfo
- Publication number
- AR093726A1 AR093726A1 ARP120100058A ARP120100058A AR093726A1 AR 093726 A1 AR093726 A1 AR 093726A1 AR P120100058 A ARP120100058 A AR P120100058A AR P120100058 A ARP120100058 A AR P120100058A AR 093726 A1 AR093726 A1 AR 093726A1
- Authority
- AR
- Argentina
- Prior art keywords
- ligand
- receptor
- composition
- group
- composition according
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composición que comprende metformina, o una sal de la misma, adaptada para liberar dicha metformina o sal de la misma en una o más regiones del intestino de un sujeto. La composición además puede comprender un ligando del receptor quimiosensor que se selecciona del grupo que consiste de un ligando de un receptor de sabor dulce, un ligando de un receptor del gusto amargo, un ligando de un receptor de umami, un ligando de un receptor de grasas, un ligando del receptor de sabor ácido y un ligando de un receptor de ácidos biliares. Reivindicación 10: Una composición de acuerdo con cualquiera de las reivindicaciones 1 - 9, caracterizada porque la composición además comprende un ligando del receptor quimiosensor que se selecciona del grupo que consiste de un ligando de un receptor de sabor dulce, un ligando de un receptor del gusto amargo, un ligando de un receptor de umami, un ligando de un receptor de grasas, un ligando del receptor de sabor ácido y un ligando de un receptor de ácidos biliares. Reivindicación 14: Una composición de acuerdo con cualquiera de las reivindicaciones 1 - 10, caracterizada porque comprende además un agente antidiabético o antiobesidad. Reivindicación 15: Una composición de acuerdo con la reivindicación 11, caracterizada porque dicho agente antidiabético está seleccionado del grupo que consiste en tiazolidindionas, sulfonilureas, meglitinidas, biguanidas, un inhibidor de a-glucosidasa, un inhibidor de DPPIV y miméticos de incretina. Reivindicación 16: Una composición farmacéutica de acuerdo a la reivindicación 20, caracterizada porque dicho agente antiobesidad está seleccionado entre el grupo que consiste en fentermina, fenfluramina, sibutramina, rimonabant, topiramato, zonisamida bupropión, naltrexona, lorcaserina y orlistat.A composition comprising metformin, or a salt thereof, adapted to release said metformin or salt thereof in one or more regions of a subject's intestine. The composition may further comprise a chemosensor receptor ligand that is selected from the group consisting of a sweet taste receptor ligand, a bitter taste receptor ligand, a umami receptor ligand, a receptor ligand fats, an acid flavor receptor ligand and a bile acid receptor ligand. Claim 10: A composition according to any one of claims 1-9, characterized in that the composition further comprises a chemosensor receptor ligand that is selected from the group consisting of a ligand of a sweet-tasting receptor, a ligand of a receptor of the Bitter taste, a ligand of a umami receptor, a ligand of a fat receptor, a ligand of the acid taste receptor and a ligand of a bile acid receptor. Claim 14: A composition according to any of claims 1-10, characterized in that it further comprises an antidiabetic or anti-obesity agent. Claim 15: A composition according to claim 11, characterized in that said antidiabetic agent is selected from the group consisting of thiazolidinediones, sulfonylureas, meglitinides, biguanides, an a-glucosidase inhibitor, a DPPIV inhibitor and incretin mimetics. Claim 16: A pharmaceutical composition according to claim 20, characterized in that said anti-obesity agent is selected from the group consisting of phentermine, fenfluramine, sibutramine, rimonabant, topiramate, zonisamide bupropion, naltrexone, lorcaserin and orlistat.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP120100058A AR093726A1 (en) | 2012-01-06 | 2012-01-06 | A COMPOSITION THAT INCLUDES METFORMIN |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP120100058A AR093726A1 (en) | 2012-01-06 | 2012-01-06 | A COMPOSITION THAT INCLUDES METFORMIN |
Publications (1)
Publication Number | Publication Date |
---|---|
AR093726A1 true AR093726A1 (en) | 2015-06-24 |
Family
ID=56117180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120100058A AR093726A1 (en) | 2012-01-06 | 2012-01-06 | A COMPOSITION THAT INCLUDES METFORMIN |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR093726A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111632033A (en) * | 2020-06-08 | 2020-09-08 | 九江学院 | Medicine composition for resisting carbapenem-resistant Klebsiella pneumoniae and preparation method and application thereof |
CN114213426A (en) * | 2021-11-18 | 2022-03-22 | 西北农林科技大学 | Application of fructus crataegi extract and its compound in preparing herbicide |
-
2012
- 2012-01-06 AR ARP120100058A patent/AR093726A1/en not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111632033A (en) * | 2020-06-08 | 2020-09-08 | 九江学院 | Medicine composition for resisting carbapenem-resistant Klebsiella pneumoniae and preparation method and application thereof |
CN114213426A (en) * | 2021-11-18 | 2022-03-22 | 西北农林科技大学 | Application of fructus crataegi extract and its compound in preparing herbicide |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20180233A (en) | OLIGONUCLEOTID COMPOSITIONS AND THEIR METHODS | |
UY37460A (en) | 1,2,4-TRIAZOLONS WITH ANALATION IN 4 AND 5 | |
MX2016012370A (en) | Antimicrobial compositions containing cationic active ingredients. | |
CL2019000935A1 (en) | Pharmaceutical composition, methods for treatment and uses thereof. | |
WO2016149501A3 (en) | Modified therapeutic agents and compositions thereof | |
AR106505A1 (en) | TREATMENT OF OLIGO-OVULATION RELATED TO HEPATIC ESTEATOSIS | |
NI201100025A (en) | METHODS OF ADMINISTRATION OF TOPICAL ANTIFUNGAL FORMULATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS. | |
CL2011001306A1 (en) | Antimicrobial composition comprising a soluble silver salt, an alkanolamide, and / or amino alcohol, a ph 6 or higher; cleansing composition comprising a surfactant, a soluble silver salt, an alkanolamide, and / or amino alcohol. | |
MX364800B (en) | Improved long-acting tilmicosin and use thereof in the treatment of bovine respiratory disease complex (brdc) and in the dry cow period. | |
AR102777A1 (en) | COMPOSITIONS OF ARNi AGAINST TMPRSS6 AND METHODS FOR USE | |
WO2015095735A3 (en) | Vaccine compositions and uses thereof | |
PE20151746A1 (en) | BICYCLE COMPOUNDS | |
MX2016014771A (en) | Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use. | |
PE20150721A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING GEMIGLIPTIN AND METFORMIN, AND METHOD FOR THEIR PREPARATION | |
PE20170430A1 (en) | ARYLHYDRAZIDES CONTAINING A FRACTION OF 2-PYRIDONE AS SELECTIVE ANTIBACTERIAL AGENTS | |
AR093726A1 (en) | A COMPOSITION THAT INCLUDES METFORMIN | |
AR055562A1 (en) | 1,3 OXAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM. | |
AR083423A1 (en) | SUPPRESSION OF AN IMMUNE TYPE 1 HYPERSENSITIVITY RESPONSE WITH AN UN RELATED ANTIGEN | |
MX2018014129A (en) | Pharmaceutical composition comprising eteplirsen. | |
AR106559A1 (en) | WATERPROOF SUSPENSION FOR ORAL ADMINISTRATION AND METHOD FOR PREPARATION | |
AR105111A1 (en) | COMPOSITION FOR ADMINISTRATION OF ACTIVE AGENTS TO AN ANIMAL | |
PE20211787A1 (en) | IMMUNOGENIC LHRH COMPOSITION AND USE OF LHRH IN PIGS | |
CL2016002721A1 (en) | A 1,1'- (1,6-dioxo-1,6-hexanediyl) bis-d-proline prodrug | |
MX2020003697A (en) | Pharmaceutical formulations comprising opioid receptor agonist as active ingredients, methods of manufacture and therapeutic uses thereof. | |
AR092168A1 (en) | PARENTERAL FORMULATIONS OF RASAGILINA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |